Tag: Indolent B-cell malignancy breakthrough

Home / Indolent B-cell malignancy breakthrough

Categories

Lisocabtagene maraleucel is granted accelerated approval by FDA for follicular lymphoma

May 2015:  Lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) has been granted rapid approval by the Food and Drug Administration. This approval is specifically for people with relapsed or ...
indolent-b-cell-malignancy-breakthrough

We Are Online! Chat With Us!
Scan the code